Urogenital carcinoma anti-TLP peptide antibodies, related kits and methods
    3.
    发明授权
    Urogenital carcinoma anti-TLP peptide antibodies, related kits and methods 失效
    泌尿生殖癌抗TLP肽抗体,相关试剂盒及方法

    公开(公告)号:US06664378B1

    公开(公告)日:2003-12-16

    申请号:US09661503

    申请日:2000-09-14

    申请人: Giulio Tarro

    发明人: Giulio Tarro

    IPC分类号: C07K1630

    CPC分类号: C07K14/4748 A61K38/00

    摘要: An antibody that binds to a specific urogenital carcinoma tumor liberated protein (TLP) epitope, wherein the TLP comprises GlyProProGluValGlnAsnAlaAsn, is described. Also described are kits comprising the antibody, and methods of identifying TLP, and methods for diagnosing urogenital carcinoma.

    摘要翻译: 描述了结合特异性泌尿生殖癌肿瘤释放蛋白(TLP)表位的抗体,其中TLP包含GlyProProGluValGlnAsnAlaAsn。 还描述了包含抗体的试剂盒和鉴定TLP的方法以及诊断泌尿生殖器癌的方法。

    Pharmaceutical composition containing interferon for the treatment of hpv infections
    4.
    发明申请
    Pharmaceutical composition containing interferon for the treatment of hpv infections 审中-公开
    含有干扰素用于治疗hpv感染的药物组合物

    公开(公告)号:US20070098687A1

    公开(公告)日:2007-05-03

    申请号:US10553387

    申请日:2004-04-06

    申请人: Giulio Tarro

    发明人: Giulio Tarro

    IPC分类号: A61K38/21

    CPC分类号: A61K38/21

    摘要: Disclosed is a liquid pharmaceutical composition containing interferon for peroral administration, and the use thereof in the treatment of infections caused by human papilloma virus (HPV).

    摘要翻译: 公开了含有用于口服给药的干扰素的液体药物组合物及其在治疗由人乳头状瘤病毒(HPV)引起的感染中的用途。

    Method of treating viral hepatitis by administration of liquid human α-interferon
    5.
    发明授权
    Method of treating viral hepatitis by administration of liquid human α-interferon 失效
    通过给予液体人α-干扰素治疗病毒性肝炎的方法

    公开(公告)号:US06884411B1

    公开(公告)日:2005-04-26

    申请号:US09125122

    申请日:1997-02-27

    CPC分类号: A61K38/212

    摘要: Use of natural human α-interferon for the preparation of a medicament in liquid form to be administered through peroral route at dosages comprised between 100 UI and 500 UI/day, for therapy of viral infections, in particular viral hepatitis, neoplasia and immune diseases in humans and animals.

    摘要翻译: 使用天然人α-干扰素制备液体形式的药物,通过口服途径以100 UI和500 UI /天之间的剂量施用,用于治疗病毒感染,特别是病毒性肝炎,瘤形成和免疫疾病 人类和动物。

    Urogenital carcinoma TLP peptides
    7.
    发明授权
    Urogenital carcinoma TLP peptides 失效
    泌尿生殖癌TLP肽

    公开(公告)号:US06222010B1

    公开(公告)日:2001-04-24

    申请号:US09051357

    申请日:1999-04-15

    申请人: Giulio Tarro

    发明人: Giulio Tarro

    IPC分类号: A61K3800

    CPC分类号: C07K14/4748 A61K38/00

    摘要: It is described a peptide consisting of a specific urogential carcinoma TLP epitope, wherein the TLP comprises the amino acid sequence GlyProProGluValGlnAsnAlaAsn. Also described are reagents to detect said urogenital TLP and pharmaceutical compositions.

    摘要翻译: 描述了由特定的泌尿器官TLP表位组成的肽,其中TLP包含氨基酸序列GlyProProGluValGlnAsnAlaAsn。 还描述了用于检测所述泌尿生殖道TLP和药物组合物的试剂。